ESG Data

アンカーリンク用

Regarding the data for FY2020 marked with ★, we have received independent assurance in our Sustainability data 2021 (PDF version) so as to bolster the reliability of the information. For details, please see the “Independent Practitioner's Assurance.”Governance Data

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Governance Data

Corporate Governance
Item		Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Board structure	Directors (Total)	Non-consolidated	Persons	7	7	8	8	8
	Independent outside directors	Non-consolidated	Persons	2	2	3	3	3
	Female directors	Non-consolidated	Persons	0	0	0	0	1
Board of Auditors structure	Auditors (Total)	Non-consolidated	Persons	4	4	4	4	4
	Independent outside auditors	Non-consolidated	Persons	2	2	2	2	2
	Female auditors	Non-consolidated	Persons	1	1	1	1	1
Director Remuneration	Total	Non-consolidated	Million yen	345	336	360	368	384
Director Remuneration	President, Representative Director, and Chief Executive Officer	Non-consolidated	Million yen	-	-	114	116	126
Auditor Remuneration	Total	Non-consolidated	Million yen	71	76	77	78	83
Number of Board of Directors meetings		Non-consolidated	Times	15	13	13	13	13
Number of Board of Auditors meetings		Non-consolidated	Times	13	13	14	14	19
Board attendance rate（directors）		Non-consolidated	%	-	100	100	100	98.6
Board attendance rate（auditors）		Non-consolidated	%	-	-	100	92.3^*1	100

The attendance rate of Audit & Supervisory Board Members excluding the Audit & Supervisory Board Member who resigned due to illness on March 27, 2020 was 100%.

Compliance
Item		Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Compliance training attendance rate		Non-consolidated	%	-	-	100	100	100
Number of reports	Discrimination and harassment related	Non-consolidated	Incidents	-	-	-	22	15
	Personnel and labor management related	Non-consolidated	Incidents	-	-	-	2	1
	Others	Non-consolidated	Incidents	-	-	-	44	6
	Total	Non-consolidated	Incidents	-	-	44	68	22
Number of compliance violations^*2	Discrimination and harassment related	Non-consolidated	Incidents	-	-	-	3	1
	Personnel and labor management related	Non-consolidated	Incidents	-	-	-	0	0
	Bribery cases	Non-consolidated	Incidents	0	0	0	0	1
	Others	Non-consolidated	Incidents	-	-	-	6	0
	Total	Non-consolidated	Incidents	-	-	5	9	2
Costs for legal violations		Non-consolidated	Million yen	-	-	-	-	0
Number of facilitation payments		Non-consolidated	Incidents	0	0	0	0	0

Those judged to be disciplinary

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Data

Research Development
Item	Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
R&D expenses	Non-consolidated	Million yen	57,506	68,821	70,008	66,497	62,384
Ratio of R&D expenses to net sales	Non-consolidated	%	23.5	26.3	24.3	22.7	20.2

Provision of Growth Opportunities
Item		Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Annual training hours per employee		Non-consolidated	Hours	-	-	35.5	30.7	34.1
Classification by training category	General capability development	Consolidated	Hours	-	-	-	39,189	69,080
	General capability development	Consolidated	Participants	-	-	-	16,194	16,867
	Professional capability development	Consolidated	Hours	-	-	-	57,226	43,214
	Professional capability development	Consolidated	Participants	-	-	-	11,012	13,072
	Compliance training	Consolidated	Hours	-	-	-	6,885	3,816
	Compliance training	Consolidated	Participants	-	-	-	13,999	33,503

For more information on the training, see "Human Resources Development."

Promoting active participation of persons with disabilities/mid-career employment
Item	Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Employment of persons with disabilities	Non-consolidated	%	2.3	2.24	2.28	2.2	2.17^*3
Number of employees hired by Mid-career recruitment（As of the end of FY）	Non-consolidated	Persons	322	380	440	446	457

As of March 31, 2021, the employment rate has been 2.17%, but we are actively recruiting, and we expect to meet the legal employment rate by October.

Employee composition
Item	Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Ratio of new graduates（male）	Non-consolidated	%	57	66	51	66	60
Ratio of new graduates（female）	Non-consolidated	%	43	34	49	34	40
Employees（total）	Non-consolidated	Persons	3,062	3,199	3,284	3,287	3,319
Employees（male）	Non-consolidated	Persons	2,358	2,629	2,682	2,676	2,688
Employees（female）	Non-consolidated	Persons	524	570	602	611	631
Contract workers ratio	Non-consolidated	%	-	0.3	0.1	0.1	0.1
Temporary staff ratio	Non-consolidated	%	-	8.8	8.9	8.0	8.8
Average age (total)	Non-consolidated	Years old	40.4	41.4	41.8	41.9	42.7
Average age (male)	Non-consolidated	Years old	41.1	42.1	42.6	42.7	43.7
Average age (female)	Non-consolidated	Years old	37.1	37.9	38	37.9	38.5
Average consecutive years of employment（total）	Non-consolidated	Years	15.3	15.3	15.5	16	16.3
Average consecutive years of employment（male）	Non-consolidated	Years	15.9	16	16.3	16.8	17.2
Average consecutive years of employment（female）	Non-consolidated	Years	12.3	11.8	12	12.4	12.5

Employee information
Item	Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Average annual salary	Non-consolidated	JPY 10,000	897	906	917	928	937
Collective bargaining rights holding rate	Non-consolidated	%	-	-	-	97.3	95.7
Labor union participation rate	Non-consolidated	%	68.6	66.8	65.1	60.8	62.2
Employee satisfaction rate (total)	Non-consolidated	%	62	-	66	-	54^*4
Employee satisfaction rate (male)	Non-consolidated	%	-	-	68	-	56
Employee satisfaction rate (female)	Non-consolidated	%	-	-	57	-	45
Female manager rate	Non-consolidated	%	3.4	3.9	4.0	4.6	4.6

The index and calculation method for employee satisfaction was changed in FY2020. When calculated using the indicators from the 2018 survey, it is 70% in 2020.

Turnover and retention rate
Item	Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Retention rate after 3 years（total）	Non-consolidated	%	89.9	97.8	97.8	93.9	96.6
Retention rate after 3 years（male）	Non-consolidated	%	93.1	98.4	96.1	95.4	97.7
Retention rate after 3 years（female）	Non-consolidated	%	85.4	96.9	100.0	90.9	95.3
Full-time employee turnover rate （voluntary resignation）	Non-consolidated	%	1.0	1.3	1.5	1.6	1.2
Full-time employee turnover rate （Mandatory retirement, etc.）	Non-consolidated	%	0.9	0.7	0.6	0.2	1.1
Full-time employee turnover rate （total）	Non-consolidated	%	1.9	2.0	2.1	1.8	2.3

Enhancing cultivation of employee-friendly workplaces
Item	Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Overtime hours	Non-consolidated	％ compared to FY2014	-	▽0.5％	▽5.7%	▽14.5%	▽3.8%
Percentage of paid vacation taken	Non-consolidated	％ compared to FY2014	-	△6.4％	△17.2％	△24.7％	△18.6％

Health and safety
Item		Scope	Unit	FY2016	FY2017	FY2018	FY2019	★FY2020
Industrial accident	Number of lost-time injuries	All Japanese operation sites （Employees）^*5	Incidents	1	1	1	0	3
	Number of lost-time injuries	All Japanese operation sites （Temporary employees）^*7	Incidents	-	-	-	1	0
	Lost-time injury frequency rate^*6	All Japanese operation sites （Employees）^*5	-	0.16	0.16	0.15	0	0.47
	Lost-time injury frequency rate^*6	All Japanese operation sites （Temporary employees）^*7	-	-	-	-	2.09	0

Scope before FY2016: Domestic plants and research institutes
Lost-time injury frequency rate = (number of lost-time injuries / total number of actual working hours) x 1,000,000
The data on the number of lost-time injuries and the lost-time injury frequency rate for temporary employees are subject to disclosure from FY2019.

Supporting disease prevention, early detection and early treatment
Item		Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Medical checkups received		Non-consolidated	%	-	99.1	99.4	99.7	99.5
Cancer screening rate	Stomach cancer screening	Non-consolidated	%	-	97.2	97.3	97.7	95.3
	Lung cancer screening	Non-consolidated	%	-	99.3	99.7	99.9	99.9
	Colorectal cancer screening	Non-consolidated	%	-	93.9	93.6	95.8	94.7
	Breast cancer screening	Non-consolidated	%	-	90	88.3	86.7	89.3
	Cervical cancer	Non-consolidated	%	-	43.4	42.3	47.3	46.6

Mental health measures and health promotion
Item		Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Stress checks received		Non-consolidated	%	-	95.1	99.4	99.8	99.5
Number of participants in walking campaign	Employees	Non-consolidated	Persons	887	1,088	1,169	1,450	1,417
	Family	Non-consolidated	Persons	256	472	771	987	985
	Temporary staff, etc.	Non-consolidated	Persons	68	99	90	124	89
Walking campaign total employee participation rate		Non-consolidated	%	-	34	35	44	42

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Environmental Data

GHG emissionsThe scope of environmental data is non-consolidated basis.
Since the figures in the table are rounded, the breakdown totals may not always coincide with the overall totals.
Item			Scope	Unit	FY2016	FY2017	FY2018	FY2019	★FY2020
GHG emissions (Market-basis)			Production and research sites	kt-CO₂	27.3	27.2	26.1	25.2	24.1
			Headquarters and other Sites in Japan（including tenant locations）	kt-CO₂	2.6	2.6	2.4	2.1	2.0
			Total	kt-CO₂	29.9	29.8	28.5	27.3	26.1
GHG emissions scope breakdown (Market-basis)	Scope 1 (Breakdown by GHG type）	Energy-derived CO₂	All operation sites	kt-CO₂	8.5	8.5	9.0	9.7	10.0
		Hydrofluorocarbon (HFC)			-	0.2	0.5	0.4	0.1
		Total			8.5	8.7	9.5	10.1	10.1
	Scope 2		All operation sites	kt-CO₂	21.4	21.1	19.1	17.1	15.9

Sites where data were collected: Fujiyama Plant, Joto Pharmaceutical Product Development Center, Yamaguchi Plant (added from FY2018), Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.
GHG emissions are calculated using the following formula.
GHG emissions = Purchased electricity × Adjusted emission factor published by electric power company + Σ (Fuel consumption × Unit calorific value × Carbon emission factor × 44/12) + Σ (Fluorocarbon leakage amount × Global warming potential)
The amount of green electric power certified under the Green Energy Certificate and renewable energy certified under J-Credit Scheme are deducted.
GHG types: Based on the Greenhouse Gas Emissions Accounting, Reporting, and Disclosure System of the Act on Promotion of Global Warming Countermeasures

GHG emissions in the value chain (Scope3)
Category		Calculation method	Notes	Scope	Unit	FY2016	FY2017	FY2018	FY2019	★FY2020
Cat1	Purchased goods and services	GHG emissions (scope 1,2) volume of our major suppliers of raw materials and materials (accounting for 80% or more of our raw materials or materials purchase costs) multiplied by the ratio of the sales to ONO out of the total sales of the supplier. Ratios for other business suppliers are assumed to follow the same trend as for major suppliers, and are calculated using the ratio of GHG emissions to the transaction amount at major suppliers.	·This category is closely associated with our business activities since active pharmaceutical ingredients for manufacturing of drugs, intermediate products and research reagents are included. ·Covers production and research sites ·Figures for FY2020 are not calculated because our major suppliers had not published their CSR reports at the time of calculation.	All operation sites	kt-CO₂	97.1	8.5	8.1	11.5	-
Cat2	Capital goods	Amount of capital investment, multiplied by emission factor	Calculated based on capital goods treated as fixed assets. The fixed assets used in this calculation are essential for business activities.		kt-CO₂	27.0	52.6	60.4	26.9	25.8
Cat3	Fuel- and energy-related activities not included in scope 1 or scope 2	Amount of non-renewable electricity purchased, multiplied by emission factor	-		kt-CO₂	1.5	1.5	1.5	2.8	2.7
Cat4	Upstream transportation and distribution	Transport data on deliveries from our production sites and distribution centers to destinations, multiplied by emission factor	-		kt-CO₂	0.1	0.1	0.1	0.1	0.1
Cat5	Waste generated in operations	Weight of each type of industrial waste generated, multiplied by emission factor	-		kt-CO₂	0.3	0.3	0.3	0.3	0.3
Cat6	Business travel	Business travel costs, multiplied by emission factor	Covers travels by airplane or Shinkansen bullet train		kt-CO₂	2.2	2.5	2.3	4.0	0.4
Cat7	Employee commuting	Commuting costs, multiplied by emission factor	-		kt-CO₂	0.3	0.4	0.4	0.5	0.4
Cat8	Upstream leased assets	Cost of gasoline for leased company cars, multiplied by emission factor	-		kt-CO₂	3.5	3.5	3.3	2.9	2.0
Cat9	Downstream transportation and distribution	GHG emissions stated in CSR reports on our major pharmaceutical wholesalers, multiplied by percentage of our net sales included in all net sales of major pharmaceutical wholesalers	·Transportation and　distribution are important business activities to control distribution of and to ensure stable supply of drugs. · Figures for FY2020 are not calculated because our major pharmaceutical wholesalers had not published their CSR reports at the time of calculation.		kt-CO₂	6.2	5.3	5.3	4.9	-
Cat10	Processing of sold products	-	We make only finished products		kt-CO₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
Cat11	Use of sold products	-	No energy is consumed during the use of ONO products		kt-CO₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
Cat12	End-of-life treatment of sold products	Weight of each type of our product container or packaging disposed of as waste, multiplied by emission factor	-		kt-CO₂	0.2	0.1	0.2	0.2	0.2
Cat13	Downstream leased assets	Floor space of asset (building) owned and rented out categorized by use, multiplied by emission factor	-		kt-CO₂	0.3	0.3	0.3	0.3	0.3
Cat14	Franchises	-	ONO does not operate franchises		kt-CO₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
Cat15	Investments	-	There is no investment involving large amounts of greenhouse gas emissions.		kt-CO₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
Total					kt-CO₂	138.7	75.1	82.2	54.4	-

Categories 1 and 9 of scope 3 and their total for FY2020 are not calculated because our major suppliers and pharmaceutical wholesalers had not published their CSR reports at the time of calculation.
The emissions factors are from the “Emission Factor Database on Accounting for Greenhouse Gas Emissions throughout the Supply Chain (ver. 2.4 in FY2016 and FY2017, ver. 2.6 in FY2018, ver. 3.0 in FY2019, and ver. 3.1 in FY2020),” published by the Ministry of the Environment of Japan.

Energy consumption
Item		Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Energy consumption		Production and research sites	MWh	84,173.4	83,906.2	88,423.4	96,369.2	★98,025.2
		Headquarters and other Japan offices/sites（including tenant locations）	MWh	5,150.1	5,256.9	5,340.4	5,236.4	★5,179.1
		Total	MWh	89,323.5	89,163.1	93,763.8	101,605.6	★103,204.3
Electricity consumption	Private power generation (renewable) (solar power generation)	All operation sites	MWh	54.0	55.3	65.0	63.0	63.3
	Purchased electricity (renewable) (hydroelectric power generation)		MWh	-	-	-	1,278.0	1,954.7
	Private power generation (non-renewable)		MWh	7,967.9	7,927.0	8,856.2	8,185.3	8,566.3
	Purchased electricity (non-renewable)		MWh	41,770.2	41,820.1	43,734.4	46,351.7	45,232.2
	Total (total electricity consumption)		MWh	49,792.1	49,802.4	52,655.5	55,878.0	55,816.5
Amount of credits purchased	Solar power generation		MWh	-	-	-	2,427.0	4,946.6
Amount of credits purchased	Biomass power generation		MWh	-	-	2,900.0	2,460.9	386.2
Renewable energy usage^*8			MWh	54.0	55.3	2,965.0	6,228.9	★7,350.7
Renewable energy usage rate (renewable energy usage / total electricity consumption)			％	0.1	0.1	5.6	11.1	★13.2

Sites where data were collected: Fujiyama Plant, Joto Pharmaceutical Product Development Center, Yamaguchi Plant (added from FY2018), Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.
Renewable energy usage = Private power generation (renewable) + Purchased electricity (renewable) + Amount of credits purchased

Water intake and wastewater volume by site (unit: 1,000 m³)
Site name	River in the area	Wastewater drainage destination	FY2016		FY2017		FY2018		FY2019		★FY2020
Site name	River in the area	Wastewater drainage destination	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume
Fujiyama Plant	Fuji River	River	195.7	128.9	205.6	148.6	240.2	178.4	185.0	145.1	157.8	125.0
Joto Pharmaceutical Product Development Center	Yodo River	Sewer	7.2	7.2	5.5	5.5	6.0	6.0	5.1	5.1	4.6	4.6
Yamaguchi Plant	Fushino River	River	-	-	-	-	8.2	8.2	18.1	18.1	18.6	17.7
Minase Research Institute	Yodo River	Sewer	45.2	45.2	51.3	51.3	41.2	41.2	39.1	39.1	33.7	33.7
Fukui Research Institute	Kuzuryu River	Sewer	39.4	7.5	38.7	5.2	31.3	5.0	27.3	5.7	13.7	2.6
Tsukuba Research Institute	Lake Kasumigaura	Sewer	10.9	10.9	8.1	8.1	6.0	6.0	7.1	7.1	7.2	7.2
Head Office and other sites in Japan (including tenant locations)	Rivers/lake in the areas where major business sites are located^*9	Sewer	-	-	15.9	15.9	15.1	15.1	15.0	15.0	10.0	10.0
Total			298.4	199.7	325.1	234.6	348.0	259.9	296.7	235.2	245.6	200.8

Sites where data were collected: Fujiyama Plant, Joto Pharmaceutical Product Development Center, Yamaguchi Plant (added from FY2018), Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.
Basins of major offices: Toyohira River, Okura River, Arakawa River, Sakawa River, Kiso River, Lake Biwa, Yodo River, Ota River, Yoshino River, Naka River

Activities to reduce water consumption (rate of recycled water)
Item	Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Percentage of reused water	Production and research sites	%	-	5.9	4.8	5.5	2.0

Waste Management, and Recycling Containers and Product Packaging
Item		Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Industrial waste	Waste generated	Production and research sites	t	534.6	719.1	446.4	430.8	★502.7
	Special management industrial waste (hazardous waste)^*10	Production and research sites	t	138.1	137.0	145.6	161.9	★171.2
	final landfill disposal	Production and research sites	t	0.7	7.4	0.4	0.2	★1.1
	final landfill disposal rate	Production and research sites	%	0.1	1.0	0.1	0.1	★0.2
final landfill disposal (Non-industrial waste is included)		Production and research sites	t	10.7	18.0	9.4	6.7	5.9
Container and packaging usage	Plastic	Production	t	-	164.7	171.7	162.8	161.5
	Paper	Production	t	-	192.0	202.7	200.9	198.1
	Glass (colorless)	Production	t	-	0.0	0.0	0.0	0.0
	Glass (brown)	Production	t	-	0.3	0.3	0.3	0.2
Obligatory recycling amount	Plastic	Production	t	-	34.7	35.5	31.2	35.1
	Paper	Production	t	-	1.6	1.6	1.5	1.4
	Glass (colorless)	Production	t	-	0.0	0.0	0.0	0.0
	Glass (brown)	Production	t	-	0.0	0.0	0.0	0.0
Commissioning fee paid for recycling		Production	1,000 yen	-	1,723.0	1,650.0	1,546.0	1,814.0

Sites where data were collected: Fujiyama Plant, Joto Pharmaceutical Product Development Center, Yamaguchi Plant (added from FY2018), Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute
Of FY2017 final industrial landfill disposal volume in, the amount of waste (5.8 tons) from renovation of Joto Pharmaceutical Product Development Center was included.
Special management industrial waste (hazardous waste) is defined under the Waste Management and Public Cleansing Law as waste that has properties of explosiveness, toxicity, infectiousness, and/or possibly causing damage to human health or the living environment. We strive to manage this type of waste properly.

Prevention of Air Pollution and Water Pollution
Item		Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Emissions into the air	SOx	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	NOx	Production and research sites	t	13.8	7.8	8.4	8.1	8.1
	Particulate matter	Production and research sites	t	0.4	0.3	0.3	0.3	0.3
	PRTR substance	Production and research sites	t	0.2	0.2	0.2	0.1	0.4
Emissions into water	Wastewater	Production and research sites	1,000m³	199.7	218.7	244.8	220.2	★190.8
	BOD	Production and research sites	t	2.4	2.2	1.3	1.3	1.2
	PRTR substance	Production and research sites	t	0.0	0.0	0.0	0.0	0.0

Management of Chemicals (PRTR substances)
Item		Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Amount handled by the notified facilities	Acetonitrile	Production and research sites	t	8.3	9.0	7.2	8.5	10.4
	Normal-hexane	Production and research sites	t	3.0	3.0	2.8	3.0	2.6
	Total	Production and research sites	t	11.2	12.0	10.0	11.5	13.0
	Dioxins	Production and research sites	mg-TEQ	-	-	-	-	-
Notified release（into the air）	Acetonitrile	Production and research sites	t	0.2	0.4	0.2	0.1	0.3
	Normal-hexane	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	Total	Production and research sites	t	0.2	0.4	0.2	0.1	0.3
	Dioxins	Production and research sites	mg-TEQ	0.3	-	-	-	-
Notified release（into public waters）	Acetonitrile	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	Normal-hexane	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	Total	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	Dioxins	Production and research sites	mg-TEQ	0.0	-	-	-	-
Notified transfer（contained in waste）	Acetonitrile	Production and research sites	t	8.1	8.8	6.9	8.4	10.1
	Normal-hexane	Production and research sites	t	2.9	3.0	2.8	3.0	2.6
	Total	Production and research sites	t	10.9	11.8	9.8	11.3	12.7
	Dioxins	Production and research sites	mg-TEQ	16.8	0.0	-	-	-
Notified transfer（Into public sewage）	Acetonitrile	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	Normal-hexane	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	Total	Production and research sites	t	0.0	0.0	0.0	0.0	0.0
	Dioxins	Production and research sites	mg-TEQ	0.0	-	-	-	-
Notified release and transfer (total)	Acetonitrile	Production and research sites	t	8.3	9.0	7.2	8.5	10.4
	Normal-hexane	Production and research sites	t	3.0	3.0	2.8	3.0	2.6
	Total	Production and research sites	t	11.2	12.0	10.0	11.5	13.0
	Dioxins	Production and research sites	mg-TEQ	17.0	-	-	-	-

Management of Chemicals (PCB)
Item		Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Joto Pharmaceutical Product Development Center	Stored（Fluorescent lamp）	Stand	552	552	552	0	0
Joto Pharmaceutical Product Development Center	Disposed	Stand	6	6	6	558	559
Minase Research Institute	Disposed	Stand	2	2	2	2	2

Joto Pharmaceutical Product Development Center in FY2007, FY2019 and in FY2020 and Minase Research Institute in FY2014 delivered PCBs to the Japan Environmental Storage & Safety Corporation, a PCB waste treatment service provider. A condenser was identified by reinspection of Joto Pharmaceutical Product Development Center in FY2020, which was disposed of in that fiscal year.

Environmental Management
Item	Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Status of acquisition of ISO 14001 certification for sites	Production	site	100%	100%	100%	100%	100%

Scope of ISO 14001 certification at production sites.

Environmental Violations
Item	Scope	Unit
Number of breaches of legal obligation/regulatory violations	All operation sites	Cases
Amount of breach-/violation-related fines	All operation sites	Million yen
Environmental liabilities as of fiscal year-end	All operation sites	Million yen

Breach/violation cases with fines of USD 10,000 or more
The above includes violations related to air and soil pollution, noise, vibration, and water quality.

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Contribution Activities Data

Initiatives for medical advancement
Item	Scope	Unit	FY2016	FY2017	FY2018	FY2019	FY2020
Osamu Hayaishi Memorial Award	-	Persons	-	1	1	1	1
Recipients of theresearch grant	-	Persons	12	12	12	12	12
Recipients of theresearch scholarship grant（40 years old and below）	-	Persons	16	16	16	16	16
Recipients of the Osamu Hayaishi Memorial Scholarship for Study Abroad	-	Persons	8	8	8	8	8

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system